AEGEAN Shows Benefit with the Addition of Perioperative Durvalumab to Neoadjuvant Chemotherapy in Resectable NSCLC
Fred GebhartDr. Tetsuya Mitsudomi, who presented the data at WCLC 2023, said regardless of disease stage, the addition of perioperative durvalumab did not adversely impact the feasibility, type, approach, or timing of surgery for participants in the trial. Read more
World Conference Plenary Addresses Barriers to—and Opportunities for—Lung Cancer Care in Low- to Middle-Income Countries
Jennifer Cable, PhDDrs. Mariam Jamal-Hanjani, Alan Sihoe, Anil Tibdewal, and Ross Soo discussed challenges and strategies across the lung cancer spectrum—from early-stage to oligometastatic and advanced disease. Read more
Lectureship Award Winners Discuss Broad Thoracic Oncology Topics During WCLC 23 Plenary Session
Darcy LewisHonorees Drs. Jessica Donington, Rafal Dziadziuszko, and Jie Wang presented thought-provoking talks on return to treatment after surgery, radiation oncology in Poland, and biomarkers in small cell lung cancer. Read more
The IASLC Academy’s 2023 cohort spent months leading up to WCLC 2023 crafting case summaries in hopes of winning a spot in the association’s first case-based simulation course. Read more
Lectureship Award Winners Discuss Range of Issues in Thoracic Oncology During WCLC Plenary Session
Darcy LewisDrs. Silvia Novello, Alan Sihoe, and D. Ross Camidge kicked off the session with forward-looking talks on tobacco control and smoking cessation, surgery, and medical oncology. Read more
KRYSTAL-1 Data Demonstrates Durable Adagrasib Response Against Mutated NSCLC
Fred GebhartAfter more than 2 years, the median duration of response was 12.4 months and no new safety signals were seen, according to Dr. Shirish Gadgeel, who presented the results during WCLC 2023. Read more
First-line Nivolumab + Ipilimumab Superior to Chemotherapy in Metastatic NSCLC at 6 Years
Fred GebhartDr. Solange Peters presented new follow-up data from CheckMate 227 that show positive results regardless of PD-L1 expression. Read more
Study Shows Exhaled Breath May Track Treatment Response in Mesothelioma
Fred GebhartDuring WCLC 2023, researcher Dr. Kevin Lamote shared data that demonstrated VOCs in exhaled breath could be a useful biomarker. Read more
IASLC’s New 5-Year Strategic Plan Unveiled at Business Meeting
Cody HoltIASLC leaders also shared highlights from the association’s membership growth and financial report and officially welcomed President Dr. Paul Van Schil. Read more
MARS2: Decortication Plus Chemotherapy Associated with Worse Outcomes for Resectable Mesothelioma
Fred GebhartDuring the Presidential Plenary, investigator Dr. Eric Lim shared data comparing surgery plus chemotherapy to chemotherapy alone, one of several potentially practice-changing studies presented during the session. Read more